"In addition to access to BD Biosciences' unparalleled portfolio of cellular research tools, Cytopeia's customers will benefit from our high- quality manufacturing and global customer support capabilities," Kozy said.
BD Biosciences is a pioneer and leader in the field of flow cytometry for cellular analysis. BD manufactured the first BD FACS(TM) (fluorescence- activated cell sorting) system in 1973. Today, BD Biosciences offers broad portfolios of research and clinical flow cytometry platforms and reagents designed for cellular characterization and sorting, as well as tools to aid in drug discovery and the growth of living cells and tissue.
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit http://www.bd.com.
This press release contains certain estimates and other forward-looking
statements (as defined under Federal securities laws) regarding BD's
performance, including future revenues, products, earnings per share and
income, or events or developments that BD expects
|SOURCE BD (Becton, Dickinson and Company)|
Copyright©2008 PR Newswire.
All rights reserved